Hydronopol substituted benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors
US7851630B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Sep 29, 2004 |
| Grant date | Dec 14, 2010 |
| Priority date | — |
| Expiry date | Oct 21, 2028 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D403/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to a group of hydronopol substituted benzimidazolone and quinazolinone derivatives which are agonists on human ORL1 (nociceptin) receptors. The invention also relates to the preparation of these compounds, to pharmaceutical compositions containing a pharmacologically active amount of at least one of these novel benzimidazolone and quinazolinone derivatives as an active ingredient, as well as to the use of these pharmaceutical compositions for the treatment of disorders in which ORL1 receptors are involved.The invention relates to compounds of the general formula (1)wherein the symbols have the meanings as given in the description.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.